First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: Jun 6, 2024

Gemini Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gemini Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
G
Gemini Therapeutics Inc
NASDAQ:GMTX
Capital Expenditures
-$151k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$795m
CAGR 3-Years
3%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$581m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$998m
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$464.7m
CAGR 3-Years
-14%
CAGR 5-Years
-41%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$809.1m
CAGR 3-Years
-13%
CAGR 5-Years
-16%
CAGR 10-Years
-15%

See Also

What is Gemini Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-151k USD

Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Capital Expenditures amounts to -151k USD.

What is Gemini Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 1Y
-113%

Over the last year, the Capital Expenditures growth was -113%.